Boston Scientific Co. (NYSE:BSX) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 4.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,170,149 shares of the medical equipment provider's stock after purchasing an additional 49,683 shares during the period. The Manufacturers Life Insurance Company owned about 0.08% of Boston Scientific worth $104,518,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Optiver Holding B.V. acquired a new position in Boston Scientific during the fourth quarter valued at approximately $187,000. Berger Financial Group Inc grew its holdings in Boston Scientific by 23.3% during the fourth quarter. Berger Financial Group Inc now owns 10,178 shares of the medical equipment provider's stock worth $909,000 after purchasing an additional 1,922 shares during the period. Gerber Kawasaki Wealth & Investment Management bought a new position in Boston Scientific during the fourth quarter worth about $222,000. Prosperity Consulting Group LLC boosted its holdings in shares of Boston Scientific by 6.0% during the fourth quarter. Prosperity Consulting Group LLC now owns 13,777 shares of the medical equipment provider's stock worth $1,231,000 after acquiring an additional 775 shares during the period. Finally, Aquatic Capital Management LLC boosted its holdings in shares of Boston Scientific by 6.9% during the fourth quarter. Aquatic Capital Management LLC now owns 163,410 shares of the medical equipment provider's stock worth $14,596,000 after acquiring an additional 10,510 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 0.3 %

NYSE:BSX traded up $0.29 on Thursday, reaching $103.16. 8,205,533 shares of the company's stock were exchanged, compared to its average volume of 6,347,818. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $152.59 billion, a price-to-earnings ratio of 82.53, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The business has a fifty day moving average of $98.53 and a 200-day moving average of $95.13. Boston Scientific Co. has a 52-week low of $70.97 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the previous year, the company earned $0.56 earnings per share. Boston Scientific's quarterly revenue was up 20.9% compared to the same quarter last year. As a group, analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares of the company's stock, valued at approximately $3,441,592.37. This trade represents a 11.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 138,009 shares of company stock worth $14,407,381 over the last ninety days. 0.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Truist Financial lifted their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Royal Bank of Canada upped their price target on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Needham & Company LLC lifted their price objective on Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Wells Fargo & Company lifted their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Finally, Robert W. Baird boosted their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Twenty-three research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $114.52.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.